scispace - formally typeset
Journal ArticleDOI

Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.

Reads0
Chats0
TLDR
The results may indicate that ARBs have a superior effect compared with placebo or other antihypertensive drugs in order to prevent left ventricular hypertrophy, atrial fibrillation, stroke, renal disease and diabetes mellitus, while there appears to be no blood pressure-independent superior effect of ARBs regarding prevention of myocardial infarction or heart failure.
Abstract
Hypertension is a high-prevalence disease that may affect several organs. In recent years, data have accumulated indicating that angiotensin II receptor blockers (ARBs) may have a supplementary effect beyond lowering blood pressure. The aim of this review is to evaluate the impact of ARBs on the most important complications of hypertension – heart, cerebrovascular and renal diseases, and metabolic complications – based on the findings from large clinical hypertension trials. The results may indicate that ARBs have a superior effect compared with placebo or other antihypertensive drugs in order to prevent left ventricular hypertrophy, atrial fibrillation, stroke, renal disease and diabetes mellitus, while there appears to be no blood pressure-independent superior effect of ARBs regarding prevention of myocardial infarction or heart failure.

read more

Citations
More filters
Journal ArticleDOI

Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients

TL;DR: Olmesartan medoxomil reduced SBP, total and LDL‐cholesterol plasma levels and urinary protein excretion and induced changes in the expression of platelet proteins which may be related to some action of the drug at the megakaryocyte level.
Journal ArticleDOI

Optimization of hypertension management: the role of angiotensin receptor blocker-calcium channel blocker combinations.

TL;DR: The combination of angiotensin receptor antagonists with calcium channel blockers has been shown to provide well-tolerated antihypertensive efficacy, which is greater than that of monotherapy with either agent, and lacks adverse metabolic effects.
Journal ArticleDOI

Management of hypertension in the outpatient setting.

TL;DR: The treatment of hypertension on an outpatient basis should be approached in a systematic manner and ongoing attention should be directed to long-term adherence to therapy.
Journal ArticleDOI

Downregulation of Brain Gα12 Attenuates Angiotensin II-Dependent Hypertension

TL;DR: Findings suggest that central Gα12 protein signaling pathways play an important role in the development of chronic AngII-dependent hypertension in rats.
References
More filters
Journal ArticleDOI

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

TL;DR: A WHO Consultation has taken place in parallel with a report by an American Diabetes Association Expert Committee to re‐examine diagnostic criteria and classification of diabetes mellitus and is hoped that the new classification will allow better classification of individuals and lead to fewer therapeutic misjudgements.
Journal ArticleDOI

Role of Insulin Resistance in Human Disease

TL;DR: The possibility is raised that resistance to insulin-stimulated glucose uptake and hyperinsulinemia are involved in the etiology and clinical course of three major related diseases— NIDDM, hypertension, and CAD.
Journal ArticleDOI

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

TL;DR: Throughout middle and old age, usual blood pressure is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.
Journal ArticleDOI

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

TL;DR: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Related Papers (5)